Tetsuo Ashizawa, MD

Harriet and Joe B. Foster Distinguished Chair in Neurosciences, Stanley H. Appel Department of Neurology
Professor of Neurology, Academic Institute
Full Member, Research Institute
Director, Neurosciences Research Program
Houston Methodist
Weill Cornell Medical College


Biography

Tetsuo Ashizawa, MD, formerly the executive director of the McKnight Brain Institute at the University of Florida, organized and developed interdisciplinary neuroscience research programs involving multiple colleges and departments. He also chaired the neurology department at the University of Texas Medical Branch and at the University of Florida, where he supervised the clinical care of and research in a variety of neurological disorders.

As a physician-scientist, some of Dr. Ashizawa’s current research is funded by the National Institutes of Health, the Muscular Dystrophy Association and the Myotonic Dystrophy Foundation. He is studying neurogenetic disorders caused by expansions of DNA sequences that are connected end-to-end and abnormally repeated, such as myotonic dystrophies, spinocerebellar ataxias, Friedreich’s ataxia, and Huntington’s disease.

Dr. Ashizawa received his medical degree from the Keio University School of Medicine in Tokyo. After moving to the U.S., he completed his neurology residency and Muscular Dystrophy Association fellowships in neurochemistry and clinical neuromuscular disorders at Baylor College of Medicine. 

Dr. Ashizawa is board certified in neurology by the American Board of Psychiatry and Neurology. He serves on multiple grant review panels, including NIH study sections, and on the scientific advisory boards of the Myotonic Dystrophy Foundation, the National Ataxia Foundation, and the Association Française contre les Myopathies.

Areas Of Expertise

Hereditary cerebellar ataxias Multiple system atrophy - cerebellar type Friedreich’s ataxia Myotonic dystrophy Facioscapulohumeral muscular dystrophy Limb girdle muscular dystrophy Huntington’s disease Fragile X associated tremor ataxia syndrome Charcot-Marie-Tooth disease
Education & Training

Fellow, Baylor College of Medicine
Residency, Baylor College of Medicine
MD, Keio University School of Medicine
Publications

Dysphagia in spinocerebellar ataxias type 1, 2, 3 and 6
Yang, CY, Lai, RY, Amokrane, N, Lin, CY, Figueroa, KP, Pulst, SM, Perlman, S, Wilmot, G, Gomez, CM, Schmahmann, JD, Paulson, H, Shakkottai, VG, Rosenthal, LS, Ying, SH, Zesiewicz, T, Bushara, K, Geschwind, M, Xia, G, Subramony, SH, Ashizawa, T, Troche, MS & Kuo, SH 2020, Journal of the Neurological Sciences, vol. 415, 116878. https://doi.org/10.1016/j.jns.2020.116878

Cancer frequency in patients with spinocerebellar ataxia type 10
Schultz, DB, Nascimento, FA, Camargo, CHF, Ashizawa, T & Teive, HAG 2020, Parkinsonism and Related Disorders, vol. 76, pp. 1-2. https://doi.org/10.1016/j.parkreldis.2020.05.032

Founder Effects of Spinocerebellar Ataxias in the American Continents and the Caribbean
on behalf of the PanAmerican Hereditary Ataxia Network 2020, Cerebellum, vol. 19, no. 3, pp. 446-458. https://doi.org/10.1007/s12311-020-01109-7

Correction: Pulse-Field capillary electrophoresis of repeat-primed PCR amplicons for analysis of large repeats in Spinocerebellar Ataxia Type 10: Pulse-Field capillary electrophoresis of repeat-primed PCR amplicons for analysis of large repeats in Spinocerebellar Ataxia Type 10 (PLoS ONE (2020) 15:3 (e0228789) DOI: 10.1371/journal.pone.0228789)
Hashem, V, Tiwari, A, Bewick, B, Teive, HAG, Moscovich, M, Le, BS, Bushara, K, Bower, M, Rasmussen, A, Tsai, YC, Clark, T, McFarland, K & Ashizawa, T 2020, PloS one, vol. 15, no. 4, e0231746, pp. e0231746. https://doi.org/10.1371/journal.pone.0231746

Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial
Kurkiewicz, A, Cooper, A, McIlwaine, E, Cumming, SA, Adam, B, Krahe, R, Puymirat, J, Schoser, B, Timchenko, L, Ashizawa, T, Thornton, CA, Rogers, S, McClure, JD & Monckton, DG 2020, PloS one, vol. 15, no. 4, e0231000, pp. e0231000. https://doi.org/10.1371/journal.pone.0231000

Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis
Chakraborty, A, Tapryal, N, Venkova, T, Mitra, J, Vasquez, V, Sarker, AH, Duarte-Silva, S, Huai, W, Ashizawa, T, Ghosh, G, MacIel, P, Sarkar, PS, Hegde, M, Chen, X & Hazra, TK 2020, Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 14, pp. 8154-8165. https://doi.org/10.1073/pnas.1917280117

Cerebellar and thalamic degeneration in spinocerebellar ataxia type 10
Arruda, WO, Meira, AT, Ono, SE, de Carvalho Neto, A, Ferreira, MG, Raskin, S, Ferreira Camargo, CH, Ashizawa, T & Ghizoni Teive, HA 2020, Parkinsonism and Related Disorders. https://doi.org/10.1016/j.parkreldis.2020.03.007

The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3
Gan, SR, Figueroa, KP, Xu, HL, Perlman, S, Wilmot, G, Gomez, CM, Schmahmann, J, Paulson, H, Shakkottai, VG, Ying, SH, Zesiewicz, T, Bushara, K, Geschwind, MD, Xia, G, Subramony, SH, Rosenthal, L, Ashizawa, T, Pulst, SM, Wang, N & Kuo, SH 2020, Parkinsonism and Related Disorders, vol. 72, pp. 37-43. https://doi.org/10.1016/j.parkreldis.2020.02.004

Pulse-Field capillary electrophoresis of repeat-primed PCR amplicons for analysis of large repeats in Spinocerebellar Ataxia Type 10
Hashem, V, Tiwari, A, Bewick, B, Teive, HAG, Moscovich, M, Schüele, B, Bushara, K, Bower, M, Rasmussen, A, Tsai, YC, Clark, T, McFarland, K & Ashizawa, T 2020, PloS one, vol. 15, no. 3, e0228789. https://doi.org/10.1371/journal.pone.0228789

Clinical and Genetic Evaluation of Spinocerebellar Ataxia Type 10 in 16 Brazilian Families
Domingues, BMD, Nascimento, FA, Meira, AT, Moro, A, Raskin, S, Ashizawa, T & Teive, HAG 2019, Cerebellum (London, England), vol. 18, no. 5, pp. 849-854. https://doi.org/10.1007/s12311-019-01064-y

Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1
Johnson, NE, Aldana, EZ, Angeard, N, Ashizawa, T, Berggren, KN, Marini-Bettolo, C, Duong, T, Ekström, AB, Sansone, V, Tian, C, Hellerstein, L & Campbell, C 2019, Neurology: Clinical Practice, vol. 9, no. 5, pp. 443-454. https://doi.org/10.1212/CPJ.0000000000000646

Spinocerebellar ataxias in Southern Brazil: Genotypic and phenotypic evaluation of 213 families
Nascimento, FA, Rodrigues, VOR, Pelloso, FC, Camargo, CHF, Moro, A, Raskin, S, Ashizawa, T & Teive, HAG 2019, Clinical Neurology and Neurosurgery, vol. 184, 105427. https://doi.org/10.1016/j.clineuro.2019.105427

Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor
Lai, RY, Tomishon, D, Figueroa, KP, Pulst, SM, Perlman, S, Wilmot, G, Gomez, CM, Schmahmann, JD, Paulson, H, Shakkottai, VG, Ying, SH, Zesiewicz, T, Bushara, K, Geschwind, M, Xia, G, Subramony, SH, Ashizawa, T & Kuo, SH 2019, Cerebellum, vol. 18, no. 3, pp. 519-526. https://doi.org/10.1007/s12311-019-01016-6

Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription
Gao, R, Chakraborty, A, Geater, C, Pradhan, S, Gordon, KL, Snowden, J, Yuan, S, Dickey, AS, Choudhary, S, Ashizawa, T, Ellerby, LM, La Spada, AR, Thompson, LM, Hazra, TK & Sarkar, PS 2019, eLife, vol. 8, e42988. https://doi.org/10.7554/eLife.42988

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
MGTX Study Group 2019, The Lancet Neurology, vol. 18, no. 3, pp. 259-268. https://doi.org/10.1016/S1474-4422(18)30392-2

Olfactory Function in SCA10
Moscovich, M, Munhoz, RP, Moro, A, Raskin, S, McFarland, K, Ashizawa, T, Teive, HAG & Silveira-Moriyama, L 2019, Cerebellum, vol. 18, no. 1, pp. 85-90. https://doi.org/10.1007/s12311-018-0954-1

Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies
Xia, G, Terada, N & Ashizawa, T 2018, Current Stem Cell Reports, vol. 4, no. 4, pp. 299-309. https://doi.org/10.1007/s40778-018-0145-5

Consensus-based care recommendations for adults with myotonic dystrophy type 1
Ashizawa, T, Gagnon, C, Groh, WJ, Gutmann, L, Johnson, NE, Meola, G, Moxley, R, Pandya, S, Rogers, MT, Greene, EP, Angeard, N, Bassez, G, Berggren, KN, Bhakta, D, Bozzali, M, Broderick, A, Byrne, JLB, Campbell, C, Cup, E, Day, JW, De Mattia, E, Duboc, D, Duong, T, Eichinger, K, Ekstrom, AB, Van Engelen, B, Esparis, B, Eymard, B, Ferschl, M, Gadalla, SM, Gallais, B, Goodglick, T, Heatwole, C, Hilbert, J, Holland, V, Kierkegaard, M, Koopman, WJ, Lane, K, Maas, D, Mankodi, A, Mathews, KD, Monckton, DG, Moser, D, Nazarian, S, Nguyen, L, Nopoulos, P, Petty, R, Phetteplace, J, Puymirat, J, Raman, S, Richer, L, Roma, E, Sampson, J, Sansone, V, Schoser, B, Sterling, L, Statland, J, Subramony, SH, Tian, C, Trujillo, C, Tomaselli, G, Turner, C, Verma, A, White, M & Winblad, S 2018, Neurology: Clinical Practice, vol. 8, no. 6, pp. 507-520. https://doi.org/10.1212/CPJ.0000000000000531

Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9
Wang, Y, Hao, L, Wang, H, Santostefano, K, Thapa, A, Cleary, J, Li, H, Guo, X, Terada, N, Ashizawa, T & Xia, G 2018, Molecular Therapy, vol. 26, no. 11, pp. 2617-2630. https://doi.org/10.1016/j.ymthe.2018.09.003

SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F
Ayhan, F, Perez, BA, Shorrock, HK, Zu, T, Banez-Coronel, M, Reid, T, Furuya, H, Clark, HB, Troncoso, JC, Ross, CA, Subramony, SH, Ashizawa, T, Wang, ET, Yachnis, AT & Ranum, LPW 2018, EMBO Journal, vol. 37, no. 19, e99023. https://doi.org/10.15252/embj.201899023

Live Chat Available